摘要
目的分析非小细胞肺癌(NSCLC)免疫检查点抑制剂相关性肺炎(CIP)的临床特征及危险因素。方法选取2021年1月至2023年12月甘肃省肿瘤医院收治的293例NSCLC患者为研究对象,进行回顾性分析,其中31例确诊为CIP,纳入CIP组,其余262例纳入非CIP组。对两组患者基线资料进行调查,分析影响CIP发生的独立危险因素。结果两组年龄、性别、体重指数、吸烟史、酗酒史、病理学分型、肿瘤分期、免疫检查点抑制剂药物类型、中性粒细胞计数(NEU)、血小板计数(PLT)比较,差异无统计学意义(P>0.05),两组血清白蛋白(ALB)、淋巴细胞计数(LYM)、嗜酸性粒细胞计数(EOS)、靶向治疗、抗血管生成治疗比较,差异有统计学意义(P<0.05);以是否为CIP为因变量Y,ALB、LYM、EOS等为自变量X,进行多元logistic回归结果显示,低水平ALB、低水平LYM、高水平EOS、采取靶向治疗、未抗血管生成治疗是CIP发生的独立危险因素(P均<0.05)。结论影响CIP发生的独立危险因素较多,包括低水平ALB、靶向治疗等,故在临床上对此类患者进行治疗时,应综合考虑患者是否存在相关危险因素,以早期进行干预。
Objective To analyze the clinical characteristics and risk factors of checkpoint inhibitor pneumonia(CIP)in patients with non-small cell lung cancer(NSCLC).Methods A total of 293 NSCLC patients admitted to Gansu Provincial Cancer Hospital from January 2021 to December 2023 were selected as the research subjects for retrospective analysis.Among them,31 cases were diagnosed with immune CIP and included in the CIP group,while the remaining 262 cases were included in the non-CIP group.The baseline data of the two groups of patients were investigated to analyze the independent risk factors influencing the occurrence of CIP.Results There was no statistically significant difference in age,gender,body mass index,smoking history,alcohol abuse history,pathological classification,tumor stage,type of immune checkpoint inhibitor drugs,neutrophil count(NEU),and platelet count(PLT)between the two groups(P>0.05).There were statistically significant differences in albumin(ALB),lymphocyte count(LYM),eosinophil count(EOS),targeted therapy,and anti-angiogenic therapy between the two groups(P<0.05).Taking whether it was CIP as the dependent variable Y and ALB,LYM,EOS,etc.as the independent variables X,multiple logistic regression was conducted.The results showed that low-level ALB,low-level LYM,high-level EOS,targeted therapy,and no anti-angiogenic therapy were independent risk factors for the occurrence of CIP(all P<0.05).Conclusion There are many independent risk factors influencing the occurrence of CIP,including low-level ALB,targeted therapy,etc.In clinical practice,a comprehensive assessment of relevant risk factors is essential for early intervention in such patients.
作者
杨鹏
王莉
周湘哲
袁宽道
YANG Peng;WANG Li;ZHOU Xiangzhe;YUAN Kuandao(Department of Critical Care Medicine,Gansu Provincial Cancer Hospital,Gansu,Lanzhou 730050,China)
出处
《中国医药科学》
2025年第12期117-120,共4页
China Medicine And Pharmacy
基金
甘肃省卫生健康行业科研计划项目(GSWSKY2021-033)。
